Asset
DNL-201
Denali Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04551534 | phase1 | completed | 2017-06-01 | 2018-08-08 | Denali Therapeutics Inc. | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers |
| NCT03710707 | phase1 | completed | 2018-12-04 | 2019-12-06 | Denali Therapeutics Inc. | Study to Evaluate DNL201 in Subjects With Parkinson's Disease |
FDA applications (0)
This company has no applications containing this asset.